Literature DB >> 27220635

Which factors are associated with extremely short-term survival after surgery in patients with esophageal squamous cell carcinoma?

Jingeng Liu1, Zhiru Wei2, Jun Zhang1, Wei Hu1, Zhenfei Ma1, Qinghang Liu1.   

Abstract

AIMS: Esophageal squamous cell carcinoma (ESCC) is associated with a short median survival and low cure rates. The postoperative survival time of some patients with ESCC is extremely short. It is important to understand risk factors in subsets of patients associated with extremely short-term survival. The standard factors such as T and N stage, which are predictive of actuarial survival, become less important as patients live for ≤1 year. However, the prevalence of these factors in these patient populations has not been well documented. We evaluated factors predictive of ≤1 year survival in this research.
METHODS: We analyzed 1596 patients underwent esophagectomy for ESCC retrospectively. The demographic and clinicopathologic characteristics were compared between patients who died within 1 year of esophagectomy and patients who survived more than 1 year after esophagectomy.
RESULTS: Univariate analysis showed significant differences between the two groups regarding gender, weight loss, comorbidity, neoadjuvant treatment, completeness of resection, pathological T stage, pathological N stage, histologic grade, the number of metastatic lymph nodes, postoperative complications, postoperative pulmonary infection and postoperative hospital stay. Based on logistic regression analysis, significant factors associated with extremely short-term survival were male gender, incomplete tumor resection, higher pathological T stage, higher pathological N stage and postoperative pulmonary infection.
CONCLUSION: The independent positive predictors for extremely short-term survival are male gender, incomplete tumor resection and postoperative pulmonary infection besides higher pathological T stage and higher pathological N stage.
© 2016 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  esophageal squamous cell carcinoma; esophagectomy; prognosis

Mesh:

Year:  2016        PMID: 27220635     DOI: 10.1111/ajco.12503

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  6 in total

1.  Integrin α5 promotes migration and cisplatin resistance in esophageal squamous cell carcinoma cells.

Authors:  Sicong Hou; Weiguo Jin; Weiming Xiao; Bin Deng; Dacheng Wu; Jiehua Zhi; Keyan Wu; Xiaowei Cao; Shuai Chen; Yanbing Ding; Hongcan Shi
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

2.  Construction and evaluation of prognostic models for esophageal cancer patients with distant and non-distant metastases: providing a reference process for clinical diagnosis and treatment.

Authors:  Mingxin Zhang; Manli Cui; Qianqian Zuo; Li Wang; Jia Wang; Lin Zhu; Rong Yan; Ning Lu; Honglin Yan; Lingmin Zhang
Journal:  J Gastrointest Oncol       Date:  2021-08

3.  Survival based radiographic-grouping for esophageal squamous cell carcinoma may impact clinical T stage.

Authors:  Wenjie Cai; Jiade J Lu; Rongyu Xu; Peiling Xin; Jun Xin; Yayun Chen; Bingzhong Gao; Jieyun Chen; Xiyang Yang
Journal:  Oncotarget       Date:  2018-01-09

4.  OTUD1 Activates Caspase-Independent and Caspase-Dependent Apoptosis by Promoting AIF Nuclear Translocation and MCL1 Degradation.

Authors:  Qingyu Luo; Xiaowei Wu; Pengfei Zhao; Yabing Nan; Wan Chang; Xiaolin Zhu; Dan Su; Zhihua Liu
Journal:  Adv Sci (Weinh)       Date:  2021-02-08       Impact factor: 16.806

5.  Expression of Insulin-Like Growth Factor Binding Protein-5 (IGFBP5) Reverses Cisplatin-Resistance in Esophageal Carcinoma.

Authors:  Dessy Chan; Yuanyuan Zhou; Chung Hin Chui; Kim Hung Lam; Simon Law; Albert Sun-Chi Chan; Xingshu Li; Alfred King-Yin Lam; Johnny Cheuk On Tang
Journal:  Cells       Date:  2018-09-20       Impact factor: 6.600

6.  Exosomal lncRNA FAM225A accelerates esophageal squamous cell carcinoma progression and angiogenesis via sponging miR-206 to upregulate NETO2 and FOXP1 expression.

Authors:  Chunyu Zhang; Yan Luo; Jingjing Cao; Xiaoyu Wang; Zhiwei Miao; Guoqing Shao
Journal:  Cancer Med       Date:  2020-10-02       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.